• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Stereotaxis Inc.

    8/23/24 5:10:48 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $STXS alert in real time by email
    S-8 1 forms-8.htm

     

    As filed with the Securities and Exchange Commission on August 23, 2024

     

    Registration No. 333-

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT

    UNDER THE SECURITIES ACT OF 1933

     

    STEREOTAXIS, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   94-3120386

    (State or other jurisdiction

    of incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

     

    710 North Tucker Boulevard, Suite 110

    St. Louis, Missouri 63101

    (Address of Principal Executive Offices, including zip code)

     

    Stereotaxis, Inc. 2022 Stock Incentive Plan, as Amended and Restated

    Stereotaxis, Inc. 2022 Employee Stock Purchase Plan, as Amended and Restated

    (Full title of the plans)

     

    David L. Fischel

    Chief Executive Officer

    Stereotaxis, Inc.

    710 N. Tucker Blvd. Suite 110

    St. Louis, Missouri 63101

    (314) 678-6100

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    Copies to:

    Robert J. Endicott, Esq.

    Bryan Cave Leighton Paisner LLP

    One Metropolitan Square

    211 North Broadway, Suite 3600

    St. Louis, Missouri 63102-2750

    (314) 259-2000

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

      Large accelerated filer ☐ Accelerated filer ☐
      Non-accelerated filer ☒ Smaller reporting company ☒
        Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     


    EXPLANATORY NOTE

    REGISTRATION OF ADDITIONAL SHARES

    PURSUANT TO GENERAL INSTRUCTION E

     

    On May 15, 2024, at the Annual Meeting of Shareholders of Stereotaxis, Inc. (the “Registrant” or “Company”), the shareholders of the Company approved an amendment (the “Incentive Plan Amendment”) to the 2022 Stock Incentive Plan (the “2022 Incentive Plan”), which the Company’s Board of Directors (the “Board”) had previously approved on February 15, 2024, subject to such shareholder approval. The 2022 Incentive Plan was originally adopted by the Board on February 3, 2022, and the Compensation Committee of the Board of Directors, on February 27, 2022, further revised the Plan, and the Plan was approved by our shareholders on May 19, 2022.

     

    The Incentive Plan Amendment provides for an increase in the number of shares authorized for issuance under the 2022 Incentive Plan by 4,000,000 shares. Previously, 4,107,114 shares were authorized under the 2022 Incentive Plan and registered under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to a registration statement on Form S-8 previously filed on August 11, 2022 (Registration No. 333-266776) (the “Previous S-8”), which remains in full force and effect.

     

    On May 15, 2024, at the Annual Meeting of Shareholders of the Company, the shareholders of the Company approved an amendment (the “ESPP Amendment”) to the 2022 Employee Stock Purchase Plan (the “2022 ESPP”), which the Board had previously approved on February 15, 2024, subject to such shareholder approval. The 2022 ESPP was originally adopted by the Board on February 3, 2022, and the Compensation Committee of the Board of Directors, on February 27, 2022, further revised the Plan, and the Plan was and approved by our shareholders on May 19, 2022.

     

    The ESPP Amendment provides for an increase in the number of shares authorized for issuance under the 2022 ESPP by 250,000 shares. Previously, 203,366 shares were authorized under the 2022 ESPP and registered under the Securities Act pursuant to the Previous S-8, which remains in full force and effect.

     

    The Company is filing this Registration Statement to register under the Securities Act (i) an additional 4,000,000 shares of the Company’s Common Stock issuable under the 2022 Incentive Plan pursuant to the Incentive Plan Amendment and (ii) an additional 250,000 shares of the Company’s Common Stock issuable under the 2022 ESPP pursuant to the ESPP Amendment. These additional shares to be registered by this Registration Statement are of the same class as those securities covered by the Previous S-8. Pursuant to General Instruction E to Form S-8, the contents of the Previous S-8 are incorporated herein by reference and this Registration Statement is only required to include those items specified by such instruction with respect to the 2022 Incentive Plan and the 2022 ESPP.

     

    Unless the context otherwise requires, references made herein to “the Company,” “the Registrant,” “we,” “us,” “our” and “ours” refer to Stereotaxis, Inc. and its consolidated subsidiaries.

     

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    As permitted by the rules of the Securities Exchange Commission (“SEC”), this Registration Statement omits the information specified in Part I of Form S-8. The documents containing the information specified in Part I of this Registration Statement will be sent or given to eligible employees as specified by Rule 428(b) promulgated under the Securities Act. Such documents are not being filed with the SEC either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 promulgated under the Securities Act.

     

    1
     

     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents listed in (a) through (d) below, which are on file with the SEC, are incorporated herein by reference (except for the portions of the Registrant’s Current Reports on Form 8-K furnished pursuant to Item 2.02 or Item 7.01 thereof or otherwise not filed with the SEC which are deemed not to be incorporated by reference into this Registration Statement):

     

      (a) The Registrant’s Annual Report filed on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on March 8, 2024;
         
      (b) The Registrant’s Quarterly Reports filed on Form 10-Q for the quarterly period ended March 31, 2024, filed with the SEC on May 15, 2024, and for the quarterly period ended June 30, 2024, filed with the SEC on August 14, 2024;
         
      (c) The Registrant’s Current Reports on Form 8-K filed with the SEC on May 13, 2024, May 16, 2024, August 2, 2024, and August 12, 2024; and
         
      (d) The description of the Registrant’s common stock contained in the Registrant’s Registration Statement on Form 8-A dated September 4, 2019, registering the Registrant’s common stock under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as amended by the Description of Registrant’s securities registered pursuant to Section 12 of the Securities Exchange Act of 1934, filed as Exhibit 4.2 of the Registrant’s Form 10-K (File No. 001-36159) filed on March 8, 2024, and any further amendments or reports filed for the purpose of updating such description.

     

    In addition, all documents subsequently filed by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than those made pursuant to Item 2.02 or Item 7.01 of Form 8-K or other information “furnished” to the Commission) prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents. These documents include periodic reports, such as Proxy Statements, Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K (other than the portions of those documents not deemed to be filed, which is deemed not to be incorporated by reference in this Registration Statement). Any statement contained in a document incorporated or deemed to be incorporated herein by reference shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement.

     

    Item 4. Description of Securities.

     

    The securities to be offered are registered under Section 12 of the Exchange Act and, accordingly, no description is provided hereunder.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not applicable.

     

    Item 6. Indemnification of Directors and Officers.

     

    Our amended and restated Certificate of Incorporation, as amended, provides that, to the fullest extent permitted by the Delaware General Corporation Law as the same exists or may hereafter be amended, our directors shall not be liable to the Registrant or our stockholders for monetary damages for breach of fiduciary duty as a director. In addition, our amended and restated Certificate of Incorporation provides that we may, to the fullest extent permitted by law, indemnify any person made or threatened to be made a party to an action, suit or proceeding, whether criminal, civil, administrative or investigative, by reason of the fact that such person or his or her testator or intestate is or was a director, officer or employee of the Registrant, or any predecessor of the Registrant, or serves or served at any other enterprise as a director, officer or employee at the request of the Registrant.

     

    2
     

     

    Our amended and restated Bylaws provide that the Registrant shall indemnify our directors and officers to the fullest extent not prohibited by the Delaware General Corporation Law or any other law. We are not required to indemnify any director or officer in connection with a proceeding brought by such director or officer unless (i) such indemnification is expressly required by law; (ii) the proceeding was authorized by our board of directors; or (iii) such indemnification is provided by the Registrant, in its sole discretion, pursuant to the powers vested in the Registrant under the Delaware General Corporation Law or any other applicable law. In addition, our amended and restated Bylaws provide that the Registrant may indemnify its employees and other agents as set forth in the Delaware General Corporation Law or any other applicable law.

     

    We have also entered into separate indemnification agreements with our directors and officers that require us, among other things, to indemnify each of them against certain liabilities that may arise by reason of their status or service with the Registrant or on behalf of the Registrant, other than liabilities arising from willful misconduct of a culpable nature. The Registrant is not required to indemnify under the agreement for (i) actions initiated by the director without the authorization of consent of the board of directors; (ii) actions initiated to enforce the indemnification agreement unless the director is successful; (iii) actions resulting from violations of Section 16 of the Exchange Act in which a final judgment has been rendered against the director; and (iv) actions to enforce any non-compete or non-disclosure provisions of any agreement.

     

    The indemnification provided for above provides for reimbursement of all losses of the indemnified party, including expenses, judgment, fines and amounts paid in settlement. The right to indemnification set forth above includes the right for us to pay the expenses (including attorneys’ fees) incurred in defending any such proceeding in advance of its final disposition in certain circumstances.

     

    The Delaware General Corporation Law provides that indemnification is permissible only when the director, officer, employee, or agent acted in good faith and in a manner reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe the conduct was unlawful. The Delaware General Corporation Law also precludes indemnification in respect of any claim, issue, or matter as to which an officer, director, employee, or agent shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery of the State of Delaware or the court in which such action or suit was brought shall determine that, despite such adjudication of liability, but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court deems proper.

     

    Item 7. Exemption From Registration Claimed.

     

    Not applicable.

     

    Item 8. Exhibits.

     

    The following exhibits are filed herewith or incorporated by reference into this registration statement on Form S-8.

     

    Exhibit

    Number

      Exhibit Description
    5.1   Opinion of Bryan Cave Leighton Paisner LLP
    10.1   Stereotaxis, Inc. 2022 Stock Incentive Plan, as amended and restated, filed herewith
    10.2   Stereotaxis, Inc. 2022 Employee Stock Purchase Plan, as amended and restated, filed herewith
    23.1   Consent of Ernst & Young LLP, Independent Registered Public Accountants
    23.2   Consent of Bryan Cave Leighton Paisner LLP (contained in Exhibit 5.1)
    24.1   Power of Attorney
    107.1   Filing Fee Table

     

    3
     

     

    Item 9. Undertakings.

     

    (a) The undersigned registrant hereby undertakes:

     

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

     

    (i) to include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    (ii) to reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and

     

    (iii) to include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.

     

    provided, however, that paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by registrant pursuant to Section 13 and Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.

     

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (4) That, for the purpose of determining liability under the Securities Act to any purchaser:

     

    (i) Each prospectus filed by the registrant pursuant to Rule 424(b)(3) of the Securities Act shall be deemed to be part of the Registration Statement as of the date the filed prospectus was deemed part of and included in the Registration Statement; and

     

    (ii) Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) of the Securities Act as part of this registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by Section 10(a) of the Securities Act shall be deemed to be part of and included in this registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in this registration statement or prospectus that is part of this registration statement or made in a document incorporated or deemed incorporated by reference into this registration statement or prospectus that is part of this registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in this registration statement or prospectus that was part of this registration statement or made in any such document immediately prior to such effective date;

     

    (b) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer, or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

    4
     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of St. Louis, State of Missouri, on August 23, 2024.

     

      STEREOTAXIS, INC.
         
      By: /s/ David L. Fischel
       

    David L. Fischel

    Chairman and Chief Executive Officer

       

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.

     

    Signature   Title(s)   Date
             
    /s/ David L. Fischel   Chairman of the Board and Chief Executive Officer   August 23, 2024
    David L. Fischel   (principal executive officer)    
             
    /s/ Kimberly R. Peery   Chief Financial Officer   August 23, 2024
    Kimberly R. Peery   (principal financial officer and principal accounting officer)    
             
    *   Director   August 23, 2024
    David W. Benfer        
             
    *   Director   August 23, 2024
    Myriam Curet        
             
    *   Director   August 23, 2024
    Nathan Fischel        
             
    *   Director   August 23, 2024
    Ross B. Levin        
             
    *   Director   August 23, 2024
    Arun S. Menawat        
             
    *   Director   August 23, 2024
    Nachum “Homi” Shamir        

     

    *By: /s/ Laura Spencer Garth  
      Laura Spencer Garth  
      Attorney-in-fact  

     

    5

    Get the next $STXS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $STXS

    DatePrice TargetRatingAnalyst
    12/16/2025$4.00Mkt Outperform
    Citizens JMP
    1/10/2024$5.00Buy
    ROTH MKM
    7/12/2022$6.00Buy
    Aegis Capital
    6/23/2022$6.00Buy
    B. Riley Securities
    1/5/2022$11.00Buy
    Craig-Hallum
    1/5/2022$13.00Buy
    Loop Capital
    More analyst ratings

    $STXS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Stereotaxis Receives FDA Approval for MAGiC Ablation Catheter

    ST. LOUIS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it obtained U.S. Food and Drug Administration (FDA) approval for the MAGiC™ Magnetic Interventional Ablation Catheter. "FDA approval of MAGiC is a significant milestone for Stereotaxis and the community of physicians pioneering robotics in electrophysiology. It ensures the benefits of Robotic Magnetic Navigation can support patients with complex and critical heart rhythm disorders, represents a major advance in robotic cardiac ablation technology, and provides a foundation for continued technological and cl

    1/6/26 8:01:00 AM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Stereotaxis to Participate in Piper Sandler 37th Annual Healthcare Conference

    ST. LOUIS, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that the company will participate in the Piper Sandler 37th Annual Healthcare Conference. David Fischel, Stereotaxis Chairman and CEO, is scheduled to participate in a fireside discussion on Wednesday, December 3rd, 2025, at 9:00 am Eastern Standard Time and will be available that same day for one-on-one meetings. "This is an exciting period for Stereotaxis as we achieve key regulatory milestones and demonstrate early commercial growth," said Mr. Fischel. "We look forward to engaging with investors at the

    11/24/25 8:58:26 AM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Stereotaxis Reports 2025 Third Quarter Financial Results

    ST. LOUIS, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third quarter ended September 30, 2025. "We continue to focus on driving commercial progress while advancing a robust portfolio of technologies through regulatory and development milestones," said David Fischel, Chairman and CEO. "This is an exciting milestone-rich period in which we are demonstrating the tangible reality and initial commercial impact of our comprehensive innovation strategy." "Our commercial progress includes two Genesis robotic systems ordered by hospitals si

    11/11/25 4:01:00 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STXS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Menawat Arun Swarup was granted 46,948 shares, increasing direct ownership by 5% to 992,457 units (SEC Form 4)

    4 - Stereotaxis, Inc. (0001289340) (Issuer)

    1/2/26 4:15:30 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Benfer David was granted 46,948 shares, increasing direct ownership by 10% to 515,872 units (SEC Form 4)

    4 - Stereotaxis, Inc. (0001289340) (Issuer)

    1/2/26 4:15:28 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Curet Myriam was granted 46,948 shares, increasing direct ownership by 14% to 392,058 units (SEC Form 4)

    4 - Stereotaxis, Inc. (0001289340) (Issuer)

    1/2/26 4:15:27 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STXS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citizens JMP initiated coverage on Stereotaxis with a new price target

    Citizens JMP initiated coverage of Stereotaxis with a rating of Mkt Outperform and set a new price target of $4.00

    12/16/25 9:03:46 AM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    ROTH MKM initiated coverage on Stereotaxis with a new price target

    ROTH MKM initiated coverage of Stereotaxis with a rating of Buy and set a new price target of $5.00

    1/10/24 8:16:33 AM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Aegis Capital initiated coverage on Stereotaxis with a new price target

    Aegis Capital initiated coverage of Stereotaxis with a rating of Buy and set a new price target of $6.00

    7/12/22 9:20:32 AM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STXS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Isaac Paul J bought $66,600 worth of shares (30,000 units at $2.22), increasing direct ownership by 11% to 97,299 units (SEC Form 4)

    4 - Stereotaxis, Inc. (0001289340) (Issuer)

    11/18/25 3:22:17 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Isaac Paul J bought $68,780 worth of shares (38,000 units at $1.81), increasing direct ownership by 77% to 87,299 units (SEC Form 4)

    4 - Stereotaxis, Inc. (0001289340) (Issuer)

    3/11/25 3:38:02 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Isaac Paul J bought $44,836 worth of shares (24,788 units at $1.81), increasing direct ownership by 90% to 49,066 units (SEC Form 4)

    4 - Stereotaxis, Inc. (0001289340) (Issuer)

    3/10/25 10:32:20 AM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STXS
    SEC Filings

    View All

    SEC Form 10-Q filed by Stereotaxis Inc.

    10-Q - Stereotaxis, Inc. (0001289340) (Filer)

    11/12/25 3:39:18 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Stereotaxis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - Stereotaxis, Inc. (0001289340) (Filer)

    11/12/25 9:00:47 AM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 424B5 filed by Stereotaxis Inc.

    424B5 - Stereotaxis, Inc. (0001289340) (Filer)

    8/29/25 5:26:30 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STXS
    Leadership Updates

    Live Leadership Updates

    View All

    Stereotaxis Technology to be Featured at Heart Rhythm Society's HRX 2025

    ST. LOUIS, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced its technology will be featured during the upcoming HRX digital health conference taking place September 4-6, 2025, in Atlanta, Georgia. HRX, an initiative pioneered by the Heart Rhythm Society, is focused on exploring digital technologies that advance the frontiers of cardiovascular medicine. Stereotaxis CEO, David Fischel, will participate in a roundtable discussion on September 5th at 3:45 PM EDT. Later that day, at 4:45 PM EDT, a distinguished panel of electrophysiologists, including Dr. Daniel Cooper,

    8/28/25 7:47:00 AM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Stereotaxis Technology to be Featured at Annual Meeting of the Society for Cardiac Robotic Navigation

    ST. LOUIS, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will participate in the Society for Cardiac Robotic Navigation's Annual Meeting taking place October 28-29 in Lisbon, Portugal. The global physician-led Society for Cardiac Robotic Navigation (SCRN) is dedicated to establishing a community and platform for users of robotic technologies in cardiology. The annual SCRN conference provides a venue for physicians and healthcare professionals to share best practices, discuss new clinical literature, and evaluate the latest innovations in technology. The

    10/21/24 8:41:13 AM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Stereotaxis Strengthens Board of Directors with Appointment of Nachum Shamir

    ST. LOUIS, July 18, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announced the appointment of Nachum "Homi" Shamir to its Board of Directors. Mr. Shamir most recently served as Chairman and Chief Executive Officer of Luminex Corporation from 2014 through its sale to DiaSorin S.p.A. for $1.8 Billion in 2021. Prior to Luminex, Mr. Shamir served as President and Chief Executive Officer of Given Imaging from 2006 through its sale to Covidien for $1 Billion in 2014. He currently serves as Chairman of Mediwound, a publicly-traded leader in enzymatic therapeutics for burn and wound-care, and SSI Diagnosti

    7/18/24 4:13:00 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STXS
    Financials

    Live finance-specific insights

    View All

    Stereotaxis Reports 2025 Third Quarter Financial Results

    ST. LOUIS, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third quarter ended September 30, 2025. "We continue to focus on driving commercial progress while advancing a robust portfolio of technologies through regulatory and development milestones," said David Fischel, Chairman and CEO. "This is an exciting milestone-rich period in which we are demonstrating the tangible reality and initial commercial impact of our comprehensive innovation strategy." "Our commercial progress includes two Genesis robotic systems ordered by hospitals si

    11/11/25 4:01:00 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Stereotaxis to Report Third Quarter 2025 Financial Results on November 11, 2025

    ST. LOUIS, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 third quarter on Tuesday, November 11, 2025 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the Company's results and corporate developments. What:Stereotaxis third quarter 2025 financial results conference callWhen:Tuesday, November 11, 2025, at 4:30 p.m. ET (1:30 p.m. PT)Dial In Number:To access the live call, dial 800-715-9871 (US and Canada) or 646-307-1963 (Internationa

    10/21/25 9:00:00 AM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Stereotaxis Reports 2025 Second Quarter Financial Results

    ST. LOUIS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the second quarter ended June 30, 2025. "We are pleased with our commercial results in the quarter. Sequential and year-over-year growth in both recurring and system revenue reflects the early positive impact of our innovations on commercial adoption," said David Fischel, Chairman and CEO. "This is an exciting milestone rich year with broad-based progress across the late stages of our comprehensive innovation strategy." "Recent FDA clearance of MAGiC Sweep was a significant milestone a

    8/7/25 4:01:00 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STXS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Stereotaxis Inc. (Amendment)

    SC 13G/A - Stereotaxis, Inc. (0001289340) (Subject)

    2/14/24 4:26:22 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Stereotaxis Inc. (Amendment)

    SC 13G/A - Stereotaxis, Inc. (0001289340) (Subject)

    2/14/23 4:32:50 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Stereotaxis Inc. (Amendment)

    SC 13G/A - Stereotaxis, Inc. (0001289340) (Subject)

    2/14/22 5:07:16 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care